Prof Pui's Talk on Clofarabine


Published on

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Prof Pui's Talk on Clofarabine

  1. 1. PAEDIATRIC LEUKAEMIA AFTERNOON SYMPOSIUMOrganizer: Paediatric Haematology & Oncology Unit, HKL, Institute for Medical Research (IMR) & Malaysian Society of Paediatric Haematology & Oncology (MASPHO)Date: March 18, 2011 [Friday]Time: 3:30 PM Introduction by Dr. Hishamshah Ibrahim MD 3:35 PM Lecture by Dr. Pui Ching-Hon MD Clofarabine: A novel nucleoside analog in paediatric leukaemia Member, St. Jude Faculty Chair, Department of Oncology Co-Leader, Hematological Malignancies Program Fahad Nassar Al-Rashid Chair of Leukemia Research American Cancer Society Professor Medical Director, China Program - International Outreach 4:35 PM Q&A 4:50 PM Discussion: 1. Difficult Paediatric Leukaemia cases  Hospital Kuala Lumpur – 10”  Universiti Malaya – 10”  Universiti Kebangsaan Malaysia – 10” 2. Potential research initiatives in Paediatric Leukaemia for Malaysia – open discussion 5:50 PM Dinner (Adjourn to hotel)Venue: Auditorium Ungku Omar, Institute for Medical Research (IMR)Speakers: Dr. Ching-Hon PUI American Cancer Society Professor and Chair, Department of Oncology, St. Jude Children’s Research Hospital, Memphis, Tennessee, USAChairman: Dr. Hishamshah Ibrahim Head, Paediatric Haematology & Oncology Unit, HKL President, Malaysian Society of Paediatric Haematology and Oncology (MASPHO), MalaysiaSponsor: Genzyme Malaysia via MASPHO
  2. 2. Brief Biography of Professor Ching-Hon Pui MDChing-Hon Pui, MDMember, St. Jude FacultyChair, Department of OncologyCo-Leader, Hematological Malignancies ProgramFahad Nassar Al-Rashid Chair of Leukemia ResearchAmerican Cancer Society ProfessorMedical Director, China Program - International OutreachDepartmentsOncologyPathologyDivisionsLeukemia / LymphomaContact InformationChing-Hon Pui, MDOncologyMS 260, Room C-6056St. Jude Childrens Research Hospital262 Danny Thomas PlaceMemphis, TN 38105-3678EducationMD - National Taiwan University, TaiwanResearch Interests  Development of "Total Therapies" for children with leukemia  Evaluating the efficacy of novel antileukemic drugs or new therapeutic strategies  Applying molecular genetic, pharmacologic and immunologic discoveries to clinical problemsSelected PublicationsPui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acuteleukemias: an update. J Clin Oncol January 1, 2011.Pui CH, Pei D, Campana D, Bowman WP, Sandlund JT, Kaste SC, Ribeiro RC, Rubnitz JE, Coustan-SmithE, Jeha S, Cheng C, Metzger ML, Bhojwani D, Inaba H, Raimondi SC, Onciu M, Howard SC, Leung W,Downing JR, Evans WE, Relling MV. Improved prognosis for older adolescents with acute lymphoblasticleukemia. J Clin Oncol December 20, 2010.
  3. 3. Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J, Pounds S, Razzouk BI, Lacayo NJ, Cao X,Meshinchi S, Degar B, Airewele G, Raimondi SC, Onciu M, Coustan-Smith E, Downing JR, Leung W, PuiCH, Campana D. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: resultsof the AML02 multicentre trial. Lancet Oncol May 5, 2010.Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, Ma J, Liu W, Cheng C, Schulman BA, HarveyRC, Chen IM, Clifford RJ, Carroll WL, Reaman G, Bowman WP, Devidas M, Gerhard DS, Yang W, RellingMV, Shurtleff SA, Campana D, Borowitz MJ, Pui CH, Smith M, Hunger SP, Willman CL, Downing JR,Children’s Oncology Group. Deletion of IKZF1 and prognosis in acute lymphoblasic leukemia. N Engl JMed 360:470-480, 2009.Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, Ribeiro RC, Rubnitz JE, Raimondi SC,Onciu M, Coustan-Smith E, Kun LE, Jeha S, Cheng C, Howard SC, Simmons V, Bayles A, Metzger ML,Boyett JM, Leung W, Handgretinger R, Downing JR, Evans WE, Relling MV. Treating childhood acutelymphoblastic leukemia without prophylactic cranial irradiation. N Engl J Med 360:2730-2741, 2009.Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, White D, Hughes TP, Le Beau MM, Pui C-H,Relling MV, Shurtleff SA, Downing JR. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletionof lkaros. Nature 453:110-114, 2008.Pui C-H, Howard SC. Current management and challenges in the CNS in paediatric leukaemia.LancetOncol 9:257-268, 2008.Pui C-H, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 371:1030-1043, 2008.Pui C-H, Evans WE, Relling MV. Are children with lesser-risk B-lineage acute lymphoblastic leukemiacurable with antimetabolite therapy? Nat Clin Pract Oncol 5:130-131, 2008.Mullighan GC, Goorha S, Radtke I, Miller C, Coustan-Smith E, Dalton J, Girtman K, Mathew S, Ma J,Pounds S, Su X, Pui C-H, Relling MV, Evans WE, Shurtleff SA, Downing JR. Genome-wide analysis ofgenetic alterations in acute lymphoblastic leukemia. Nature 446:758-764, 2007.Iwamoto S, Mihara K, Downing JR, Pui C-H, Campana D. Mesenchymal cells determine the response ofacute lymphoblastic leukemia cells to asparaginase. J Clin Invest 117:1049-1057, 2007.Hijiya N, Hudson M, Lensing S, Zacher M, Onciu M, Behm FG, Razzouk BI, Ribeiro RC, Rubnitz JE,Sandlund JT, Rivera GK, Evans WE, Relling MV, Pui C-H. Cummulative incidence of secondary neoplasmsas the first event after treatment of childhood acute lymphoblastic leukemia increases over 30years. JAMA 297:1207-1215, 2007.Pui C-H, Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukemia. Nat RevDrug Discov 6:149-165, 2007.Pui C-H, Evans WE. Treatment for acute lymphoblastic leukemia. N Engl J Med 354:166-178, 2006.Cheng Q, Yang WJ, Raimondi SC, Pui C-H, Relling MV, Evans WE. Karyotypic abnormalities creatediscordance of germline genotype and cancer cell phenotypes. Nat Genet 37:878-882, 2005.Ribeiro RC, Pui CH. Saving the children-improving childhood cancer treatment in developing countries. NEngl J Med 352:2158-2160, 2005.Holleman A, Cheok MH, den Boer ML, Yang W, Veerman AJP, Kazemier KM, Pei D, Cheng C, Pui C-H, Relling MV, Janka-Schaub GE, Pieters R, Evans WE. Gene expression patterns in drug-resistant acutelymphoblastic leukemia cells and response to treatment. N Engl J Med 351:533-542, 2004.Pui C-H, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 350:1535-1548, 2004.Pui C-H, Sandlund JT, Pei D, Rivera GK, Howard SC, Ribeiro RC, Rubnitz JE, Razzouk BI, Hudson M,Cheng C, Raimondi SC, Behm FG, Downing J, Relling MV, Evans WE. Results of therapy for acutelymphoblastic leukemia in black and white children. JAMA 290:2001-2007, 2003.Pui C-H, Cheng C, Leung W, Rai SN, Rivera GK, Sandlund JT, Ribeirio RC, Relling MV, Kun LE, EvansWE, Hudson MM. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. NEng J Med 349:640-649, 2003.Cheok MH, Yang W, Pui C-H, Downing JR, Cheng C, Naeve CW, Relling MV, Evans WE. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells.NatGenet 34:85-90, 2003.Pui C-H, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps W, Silverman LB, Biondi A, Harms D,Vilmer E, Schrappe M, Camitta B. Outcome of treatment in childhood acute lymphoblastic leukaemia withrearrangements of the 11q23 chromosomal region. Lancet 359:1909-1915, 2002.Yeoh E-J, Ross MB, Shurtleff SA, Williams WK, Patel D, Mahfouz R, Behm FG, Raimondi SC, Relling MV,Patel A, Cheng C, Campana D, Wilkins D, Zhou X, Li J, Liu H, Pui C-H, Evans WE, Naeve C, Wong L,Downing JR. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblasticleukemia by gene expression profiling. Cancer Cell 1:133-143, 2002.Pui C-H, Campana D, Evans WE. Acute lymphoblastic leukemia – current status and futureperspective. Lancet Oncol 2:597-607, 2001.Howard SC, Gajjar A, Ribeirio RC, Rivera GK, Rubnitz JE, Sandlund JT, Harrison PL, deArmendi A, DahlGV, Pui C-H. Safety of lumbar puncture in children with acute lymphoblastic leukemia andthrombocytopenia. JAMA 284:2222-2224, 2000.
  4. 4. Relling MV, Pui C-H, Sandlund JT, Rivera GK, Hancock ML, Boyett JB, Schuetz EG, Evans WE. Adverseeffect of anticonvulsants on the efficacy of chemotherapy for acute lymphoblastic leukemia.Lancet 356:285-290, 2000.Aricò M, Valsecchi MG, Camitta B, Schrappe M, Chessels J, Baruchel A, Gaynon P, Sallan S, Janka G,Kamps W, Pui C-H, Masera G. Outcome of treatment of Philadelphia-chromosome positive acutelymphoblastic leukemia. N Engl J Med 342:998-1006, 2000.Relling MV, Rubnitz JE, Rivera GK, Boyett JM, Hancock M, Felix CA, Kun LE, Walter AW, Evans WE,Pui C-H. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet354:34-39,1999.Pui C-H, Evans WE. Drug Therapy: Acute lymphoblastic leukemia. N Engl J Med 339:605-615, 1998.Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui C-H. Conventional versus individualizedchemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338:499-505, 1998.Pui C-H, Boyett JM, Hughes W, Rivera GK, Hancock M, Sandlund JT, Synold T, Relling MV, Ribeirio RC,Crist WM, Evans WE. Human granulocyte colony-stimulating factor after induction chemotherapy in childrenwith acute lymphoblastic leukemia. New Engl J Med 336:1781-1787, 1997.Pui C-H. Medical Progress: Childhood leukemias. N Engl J Med 332:1618-1630, 1995.Pui C-H, Boyett JM, Hancock ML, Pratt CB, Meyer WH, Crist WM. Outcome of treatment for childhoodcancer in black as compared with white children: the St. Jude Childrens Research Hospital experience,1962 through 1992. JAMA 273:633-637, 1995.Mahmoud HH, Rivera GK, Hancock ML, Krance RA, Kun LE, Behm FG, Ribeirio RC, Sandlund JT, CristWM, Pui C-H. Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosedacute lymphoblastic leukemia. N Engl J Med 329:314-319, 1993.Pui C-H, Ribeirio RC, Hancock ML, Rivera GK, Evans WE, Raimondi SC, Head DR, Behm FG, MahmoudMH, Sandlund JT, Crist WM. Acute myeloid leukemia in children treated with epipodophyllotoxins for acutelymphoblastic leukemia. N Engl J Med 325:1682-1687, 1991.Pui C-H, Hancock ML, Raimondi SC, Head DR, Thompson E, Wilimas J, Kun LE, Bowman LC, Crist WM,Pratt CB. Myeloid neoplasia in children treated for solid tumours. Lancet 336:417-421, 1990.Pui C-H, Behm FG, Raimondi SC, Dodge RK, George SL, Rivera GK, Mirro J Jr, Kalwinsky DK, Dahl GV,Murphy SB, Crist WM, Williams DL. Secondary acute myeloid leukemia in children treated for acutelymphoid leukemia. N Engl J Med 321:136-142, 1989.